Molecular subtypes might affect chemotherapy-induced peripheral neuropathy in breast cancer patients receiving neoadjuvant chemotherapy

I want to congratulate Lee and colleagues for their article [1] in which they explored the incidence and riskfactors associated with chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients receiving neoadjuvant chemotherapy using docetaxel. Among the participants, 45% reported CIPN at the end of treatment. Among them, 42% reported persistent CIPN after discontinuation of treatment. Interestingly, the authors reported that pre-treatment anxiety was significantly associated with persistent CIPN.
Source: Journal of Psychosomatic Research - Category: Psychiatry & Psychology Authors: Tags: Letter to the editor Source Type: research